Note that NVS’ Humira-FoB program, which is using the conventional BLA pathway in the US, is not seeking US interchangeability with branded Humira. This makes it a very different business proposition from what BAX/MNTA are attempting to do with their FoB compounds.
News 
Market Data 
Discover 
